Partner Navigation for Hepatitis C and Substance Use Disorder

MM
Overseen ByMeghan Morris, PhD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, San Francisco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.

The study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted "booster" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.

Participants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.

This research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.

Who Is on the Research Team?

MM

Meghan Morris, PhD, MPH

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

This trial is for adults (18+) who inject drugs, have finished hepatitis C treatment in the last 3 months, and have a main injecting partner willing to join. Participants must speak English or Spanish and be able to give informed consent.

Inclusion Criteria

I have a main injecting partner who is willing to join the study.
I am at least 18 years old.
I am 18 years old or older.
See 7 more

Exclusion Criteria

I am able to understand and give consent for the study.
For both index participants and injecting partners: Previously participated in this study in any capacity

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

up to 25 weeks

Treatment

Participants receive HCV treatment and a Partner Navigation Intervention booster session at treatment completion

Duration not specified
1 session (in-person)

Follow-up

Participants are monitored for engagement in ongoing healthcare and session acceptability

1 week
Follow-up evaluation

What Are the Treatments Tested in This Trial?

Interventions

  • Partner Navigation Intervention Booster Session

Trial Overview

The study tests if a brief 'booster' session with both partners after finishing hepatitis C treatment helps people stay engaged in healthcare. It uses surveys, interviews, and follow-up checks to see how well this approach works.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Partner Navigation Booster SessionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials
2,636
Recruited
19,080,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+